GSK’s Rare Diseases Head Marc Dunoyer to Join AstraZeneca

While AstraZeneca prepared to eliminate over 5,000 postions, Marc Dunoyer joins its team in the hopes of supporting its global restructuring programme.

AstraZeneca (AZ) has hired former head of GSK’s rare diseases business Marc Dunoyer to support its global restructuring programme. Dunoyer joins AZ as Executive VP, Global Portfolio and Product Strategy as it prepares to axe more than 5,000 positions as part of a three-year strategy […]

Mystery Rare Disease Drug Earns Isis $5M from GSK


Sometimes, it pays to be secretive: Isis Pharmaceuticals received a $5 million milestone payment from GlaxoSmithKline (GSK) toward the development of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase II proof-of-concept, at which time GSK has the option […]

Washington Post Supplement sheds light and insights into the world of rare disease


Many Advocates, Industry, Parents, Advocacy Organizations have participated in the first in a series of Rare Disease reports being produced by Media Planet. This first report will be seen by over 4 million readers of the Washington Post, available on newsstands around the country today. […]

Another Global Pharmaceutical Company Jumping In To Help Rare Disease Community!

More news from Pharma and the giant Glaxo Smith Kline about new division focusing on rare disease – It seems that over the last 4 months we have heard about various Pharma organizations with new commitments to rare disease, focusing money and research to help […]